Credit: Shutterstock photoAccording to GuruFocus Insider Data, the recent CFO buys were: Blue Apron Holdings Inc. ( APRN ), RiceBran Technologies ( RIBT ) and Aeglea BioTherapeutics Inc. ( AGLE ).
Blue Apron Holdings Inc.: President, CEO, CFO and Treasurer Brad Dickerson bought 180,000 shares
President, CEO, CFO and Treasurer Brad Dickerson bought 180,000 shares for $3.93 per share on Dec. 13. The stock price has increased by 7.38%. Blue Apron Holdings Inc. has a market cap of $802.390 million and its shares were traded around $4.22. The company has a P/S ratio of 0.55.
SVP and Gen. Mgr. Consumer Products Timothy J Smith bought 25,000 shares for $3.89 per share on Dec. 11. The stock price has increased by 8.48%. Sr VP of Op and Fulfillment Pablo Cussatti sold 2,209 shares for $3.05 per share on Nov. 28. The stock price has increased by 38.36%. 10% Owner Round Capital IV Partner First sold 65,728 shares for $3.03 per share on Nov. 22. The stock price has increased by 39.27%.
RiceBran Technologies: CFO and EVP Brent Robert Rystrom bought 79,423 shares
CFO and EVP Brent Robert Rystrom bought 5,000 shares for $1.41 per share on Dec. 13. Since then, the stock price has increased by 3.55%. RiceBran Technologies has a market cap of $24.660 million and its shares were traded around $1.46. The company has a P/S ratio of 0.35.
RiceBran Technologies announced its 2017 second-quarter results with revenues of $3.45 million and gross profit of $1.14 million; the net income was $3.3 million. The 2016 total revenue was $39.41 million, a 1% decrease from the 2015 total revenue. The 2016 gross profit was $7.97 million, a 1% decrease from the 2015 gross profit. The 2016 net loss was $8.53 million.
CEO and President Robert D Smith bought 3,500 shares for $1.46 per share on Dec. 12. Since then, the stock price has not changed. President of USA Ingredients Michael Goose bought 2,500 shares for $1.44 per share on Dec. 14. Since then, the stock price has increased by 1.39%. Director Henk Hoogenkamp bought 6,000 shares for $1.46 per share on Dec. 12. Since then, the stock price has not changed.
Aeglea BioTherapeutics Inc.: CFO and VP Charles N York II bought 25,959 shares
CFO and VP Charles N York II bought 25,959 shares for $4.48 per share on Dec. 05. Since then, the stock price has increased by 8.71%. Aeglea Biotherapeutics Inc. has a market cap of $81.080 million and its shares were traded around $4.87. The company has a P/S ratio of 14.00.
Aeglea Biotherapeutics announced its 2017 third-quarter results with revenues and gross profit of $1.26 million; the net loss was $7.87 million. The 2016 total revenue and gross profit was $4.63 million, a 24% decrease from the 2015 total revenue. The 2016 net loss was $21.70 million.
Interim CEO Anthony G. Quinn bought 8,288 shares for $4.96 per share on Dec. 08. Since then, the stock price has decreased by 1.81%. Director Anthony G. Quinn bought 17,121 shares for $4.86 per share on Dec. 05. Since then, the stock price has increased by 0.21%.
Disclosure: none
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
